Baseline patient and disease characteristics in all patients (clinical cutoff date 12 October 2023; ITT population)
| . | Pola-M-CHP, n = 40 . | Pola-R-CHP, n = 22 . |
|---|---|---|
| Median age (range), y | 66.5 (39-81) | 63.0 (30-79) |
| 18-65 | 18 (45.0) | 16 (72.7) |
| >65 | 22 (55.0) | 6 (27.3) |
| Male | 26 (65.0) | 14 (63.6) |
| ECOG PS | n = 38 | n = 21 |
| 0 | 16 (42.1) | 13 (61.9) |
| 1 | 20 (52.6) | 7 (33.3) |
| 2 | 2 (5.3) | 1 (4.8) |
| Ann Arbor stage | ||
| I-II | 5 (12.5) | 2 (9.1) |
| III-IV | 35 (87.5) | 20 (90.9) |
| IPI score | ||
| 2 | 16 (40.0) | 8 (36.4) |
| 3 | 14 (35.0) | 12 (54.5) |
| 4 | 10 (25.0) | 2 (9.1) |
| Cell of origin | ||
| ABC | 5 (12.5) | 0 |
| GCB | 16 (40.0) | 11 (50.0) |
| Non-GCB | 18 (45.0) | 7 (31.8) |
| Unknown | 1 (2.5) | 4 (18.2) |
| Additional characterization by local laboratory | ||
| MYC, BCL2 and/or BCL6 rearrangements | 5 (12.5) | 4 (18.2) |
| Double expressor (MYC and BCL2 overexpression without translocation) | 6 (15.0) | 1 (4.5) |
| None of above | 17 (42.5) | 15 (68.2) |
| Not determined/available | 12 (30.0) | 2 (9.1) |
| Bulky disease (≥7.5 cm) | 9 (22.5) | 6 (27.3) |
| Extranodal involvement | 25 (62.5) | 17 (77.3) |
| . | Pola-M-CHP, n = 40 . | Pola-R-CHP, n = 22 . |
|---|---|---|
| Median age (range), y | 66.5 (39-81) | 63.0 (30-79) |
| 18-65 | 18 (45.0) | 16 (72.7) |
| >65 | 22 (55.0) | 6 (27.3) |
| Male | 26 (65.0) | 14 (63.6) |
| ECOG PS | n = 38 | n = 21 |
| 0 | 16 (42.1) | 13 (61.9) |
| 1 | 20 (52.6) | 7 (33.3) |
| 2 | 2 (5.3) | 1 (4.8) |
| Ann Arbor stage | ||
| I-II | 5 (12.5) | 2 (9.1) |
| III-IV | 35 (87.5) | 20 (90.9) |
| IPI score | ||
| 2 | 16 (40.0) | 8 (36.4) |
| 3 | 14 (35.0) | 12 (54.5) |
| 4 | 10 (25.0) | 2 (9.1) |
| Cell of origin | ||
| ABC | 5 (12.5) | 0 |
| GCB | 16 (40.0) | 11 (50.0) |
| Non-GCB | 18 (45.0) | 7 (31.8) |
| Unknown | 1 (2.5) | 4 (18.2) |
| Additional characterization by local laboratory | ||
| MYC, BCL2 and/or BCL6 rearrangements | 5 (12.5) | 4 (18.2) |
| Double expressor (MYC and BCL2 overexpression without translocation) | 6 (15.0) | 1 (4.5) |
| None of above | 17 (42.5) | 15 (68.2) |
| Not determined/available | 12 (30.0) | 2 (9.1) |
| Bulky disease (≥7.5 cm) | 9 (22.5) | 6 (27.3) |
| Extranodal involvement | 25 (62.5) | 17 (77.3) |
Data presented as n (%) of patients unless otherwise stated.
ABC, activated B-cell like; GCB, germinal center B-cell like.